Posted by Michael Wonder on 04 Jan 2024
ICER to assess treatment for myelodysplastic syndrome
3 January 2024 - Report will be subject of CTAF meeting in July 2024; draft scoping document open to public comment until 24 January 2024.
The ICER announced today that it will assess the comparative clinical effectiveness and value of imetelstat (Geron Corporation) for the treatment of myelodysplastic syndrome.
